title: Lamotrigine administration in panic disorder with agoraphobia.
abstract: Several anticonvulsants, although as yet not lamotrigine (LTG), have been found useful in the treatment of panic disorder with (PDA) or without agoraphobia. We administered LTG (200 mg/d) to 4 outpatients with PDA, as an augmentation therapy (3 patients with chronic and severe agoraphobia) or monotherapy (1 drug-naive patient with first-onset PDA) in a 14-week trial. The patient under LTG monotherapy improved significantly, whereas PDA symptoms in 2 of the other patients improved to some extent.
authors.affiliation: Eginition Hospital, 1st Department of Psychiatry, Athens University Medical School, Athens, Greece. vmasdrakis@med.uoa.gr
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Masdrakis
authors.forename: George N
authors.initials: GN
authors.lastname: Papadimitriou
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Oulis
mesh_terms: D000328:Adult; D000379:Agoraphobia / Q000150:complications* / Q000188:drug therapy*; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine